Pharmacogenetic investigation of smoking cessation treatment.
about
Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis.Antidepressants for smoking cessationInterventions for preventing weight gain after smoking cessationAntidepressants for smoking cessationAntidepressants for smoking cessationA systematic review of the relationships between craving and smoking cessationA review of pharmacogenetic studies of substance-related disordersCYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changesThe significant association of Taq1A genotypes in DRD2/ANKK1 with smoking cessation in a large-scale meta-analysis of Caucasian populationsSex heterogeneity in pharmacogenetic smoking cessation clinical trialsSex differences in TTC12/ANKK1 haplotype associations with daily tobacco smoking in Black and White Americans.Tobacco cessation in primary care: maximizing intervention strategies.Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data.Co-morbidity of smoking in patients with psychiatric and substance use disorders.Bupropion: pharmacology and therapeutic applications.Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians.Pharmacogenetic aspects of addictive behaviorsCytochrome P450 enzymes in the brain: emerging evidence of biological significanceBiomarkers of Response to Smoking Cessation Pharmacotherapies: Progress to Date.Biomarkers to optimize the treatment of nicotine dependence.Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessationPharmacogenetics and nicotine addiction treatment.Genetics and smoking cessation improving outcomes in smokers at riskGenetics of nicotine dependence and pharmacotherapy.A cost-effectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessationCan the blind see? Participant guess about treatment arm assignment may influence outcome in a clinical trial of bupropion for smoking cessation.Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment.Bupropion for the treatment of nicotine withdrawal and craving.Current and emerging pharmacotherapies for treating tobacco dependence.Overview of the pharmacogenomics of cigarette smoking.Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymesGenetic variation in the dopamine pathway and smoking cessation.Factors associated with discontinuation of bupropion and counseling among African American light smokers in a randomized clinical trial.Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.Reconciling human smoking behavior and machine smoking patterns: implications for understanding smoking behavior and the impact on laboratory studies.Mechanisms underlying the comorbidity of tobacco use in mental health and addictive disorders.Pharmacogenetics of alcohol, nicotine and drug addiction treatments.
P2860
Q21093272-1BE73C18-1FB5-4CEB-A818-BFCA7BCEEB9AQ24201167-F7F1D291-B2F4-4A35-BEDB-52E44A835221Q24203883-42FF7A53-E769-4984-88B0-043C1E7EBFD5Q24245969-3C47E863-F517-4837-B6CA-F3EE7BA4241DQ24246426-6062623E-A780-4CFF-A035-A6BB81ACBBA7Q27026417-4654D79F-4E27-4901-9172-D69CA1388AEFQ27312296-70071F78-29F7-4AB2-B4C0-FD7442BCA9DBQ28535164-D6B616EE-9241-4111-9D6F-A0EFCE8790E7Q30277983-8A23D9BB-ECD1-4270-AF83-233951EB66D5Q33605769-B6B92FAB-155E-4478-AC55-A4609666FD1BQ33671613-5A82CAFE-0384-4630-B061-AFBBC996016AQ33723393-5329701F-0C04-4485-AD87-55FC2EAE45B2Q33803436-23DF94EB-EA7D-4182-BC06-CB05ACAC3982Q33942653-AC010969-E93D-4195-A925-07E8F4B9AA4FQ34569990-4B4B50E2-61FC-43B8-8C65-6BFD336A0FFFQ34722733-A228456A-778B-4383-BAA2-89B34C61B2AEQ35454787-2793228E-F23D-4FE9-BEB9-B6352DB35C10Q35570962-E9C259E9-9E19-446D-9D18-546B3FCC4EB6Q35751986-B99009AE-E270-4BAF-8BE4-97388F7A7C95Q35773685-F515F720-4C9F-40AD-AFD4-50B7108A9D68Q36052831-6AA56D47-A32D-471B-BC50-B6EA0177939BQ36087706-65AE1E15-3459-4651-8699-6F5D5085A30BQ36192658-B78710E7-0ADE-4796-9829-4C0B62996A35Q36319935-35E4A7D2-517E-4B4D-A874-E7B03B81D9D0Q36453486-8925957F-7CB4-486F-9E5E-BE76345A9B81Q36481665-29D8C960-10EB-451E-AC6F-F1A38D7CF96DQ36492892-1A3C25CB-7D3E-49E5-A886-FD9139E1034DQ36511661-9F0CC709-A2A8-4F3B-846C-94194EF31288Q36532139-E3B3B5AD-76B3-476C-AD9D-C7D59A49CB13Q36580581-659289F4-5552-4218-B6A9-82B00406F736Q36708951-D9783160-A11E-4535-9B09-6E82D5794858Q36885659-095D60D2-9848-4EFB-81C6-C158ECB43A81Q37169244-6574AE6B-9866-4631-A2CC-CCF384A8EEA3Q37264547-DAA5FD75-77BE-44C3-8516-D679F9A3AA08Q37273823-AC5AF173-C3E8-4A1D-B8F9-FC483AF0617AQ37325773-A27D6E74-02D0-4201-B6C6-10DFCAF86930Q37395740-367FD711-8BC3-41AB-AB58-E15DC004D89EQ37461696-D2DF72D6-457B-4681-A03F-1E4AF1D86227Q37519956-4A2AE968-F3B8-4D25-A6E6-67DC49337607Q37848476-6C06970B-6DF3-432B-AB1C-0893778BC2E9
P2860
Pharmacogenetic investigation of smoking cessation treatment.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Pharmacogenetic investigation of smoking cessation treatment.
@en
Pharmacogenetic investigation of smoking cessation treatment.
@nl
type
label
Pharmacogenetic investigation of smoking cessation treatment.
@en
Pharmacogenetic investigation of smoking cessation treatment.
@nl
prefLabel
Pharmacogenetic investigation of smoking cessation treatment.
@en
Pharmacogenetic investigation of smoking cessation treatment.
@nl
P2093
P1476
Pharmacogenetic investigation of smoking cessation treatment.
@en
P2093
Angela Pinto
E Paul Wileyto
Janet Audrain
Larry Hawk
Leonard Epstein
Peter G Shields
Ray Niaura
Shiva Krishnan
P304
P356
10.1097/00008571-200211000-00007
P50
P577
2002-11-01T00:00:00Z